Efinopegdutide
Overview
Efinopegdutide is a long-acting dual agonist of the GLP-1 and glucagon receptors, utilizing PEGylation to extend half-life and enable once-weekly dosing. The compound combines GLP-1-mediated glycemic control and appetite reduction with glucagon-driven energy expenditure and hepatic fat mobilization. It is under investigation for obesity and metabolic dysfunction-associated steatohepatitis.
Key Research Findings
Phase 2 trials in adults with non-alcoholic steatohepatitis (now termed metabolic dysfunction-associated steatohepatitis) have demonstrated reductions in liver fat and body weight. Results published in hepatology journals in 2021 and 2022 supported progression into later-stage development. Phase 3 trials are ongoing to assess histological endpoints and cardiovascular outcomes.
Subcutaneous injection
In Clinical Trials
Interested in Efinopegdutide?
Find a verified provider experienced with Efinopegdutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Efinopegdutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.